Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
The new leader of the umbrella organ of Japanese pharma trade groups has expressed the industry’s opposition to a two-step price tweak in 2019 that the government eyes for the planned consumption tax hike in October that year, pushing for…
To read the full story
Related Article
- FY2019 Revision Should Cover Only “Half a Year’s Worth” of Price Tweaks, MHLW Insurance Chief Says for Clarification
September 3, 2018
- April 2019 Price Cut Wouldn’t Fit the Purpose of Tax Tweak: MHLW Insurance Chief
August 31, 2018
- MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
May 25, 2018
ORGANIZATION
- JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
- WHO Opens Tokyo Hub to Help Health Systems in Developing Nations
July 16, 2026
- FIRM Unveils Vision 2030 to Bolster Japan’s Regenerative Medicine Industry
July 15, 2026
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
- JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…